Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2018) 132 (Supplement 1): 804.

https://doi.org/10.1182/blood-2018-99-117871

Published: 2018

Journal Articles

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Blood (2016) 127 (13): 1656–1665.

https://doi.org/10.1182/blood-2015-10-676924

Published: 2016

Includes: Supplemental data

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina K. Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo

Blood (2014) 124 (4): 503–510.

https://doi.org/10.1182/blood-2014-03-566273

Published: 2014

Journal Articles

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Blood (2014) 123 (10): 1461–1469.

https://doi.org/10.1182/blood-2013-07-517276

Published: 2014

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

Journal Articles

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Kirsten Meid, MPH, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, MD, Christopher Patterson, Guang Yang, PhD, Zachary Hunter, Janet Kunsman, NP, Sandra Kanan, NP, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 757.

https://doi.org/10.1182/blood.V122.21.757.757

Published: 2013

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N. Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

Blood (2013) 121 (8): 1296–1303.

https://doi.org/10.1182/blood-2012-06-439307

Published: 2013

Journal Articles

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Marlise R Luskin, MD, Federico Campigotto, MS, Paul G. Richardson, MD, John Koreth, MBBS, DPhil, Irene M. Ghobrial, MD, Robert Schlossman, MD, Robert J Soiffer, MD, Nikhil C. Munshi, MD, Diane Warren, Muriel Gannon, RN, Kathleen Finn, RN, Kenneth C Anderson, MD, Edie Weller, PhD, Jacob P. Laubach, MD

Blood (2011) 118 (21): 4134.

https://doi.org/10.1182/blood.V118.21.4134.4134

Published: 2011

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Steven P Treon, MD, PhD, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, MD, Herbert Eradat, MD, MS, Stephanie A. Gregory, MD, Sheeba Thomas, MD, Ranjana Advani, MD, Rachid Baz, Ashraf Z. Badros, MD, Jeffrey Matous, MD, Kenneth C. Anderson, MD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2951.

https://doi.org/10.1182/blood.V118.21.2951.2951

Published: 2011

Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 1874.

https://doi.org/10.1182/blood.V118.21.1874.1874

Published: 2011

Journal Articles

Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients

Angela M Sousa, NP, Federico Campigotto, Donna Neuberg, ScD, Diane Warren, Paul G. Richardson, MD, Kenneth C Anderson, MD, K. Gary J. Vanasse, MD, Jacob P. Laubach, MD

Blood (2011) 118 (21): 5073.

https://doi.org/10.1182/blood.V118.21.5073.5073

Published: 2011

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Blood (2010) 116 (21): 990.

https://doi.org/10.1182/blood.V116.21.990.990

Published: 2010

NARROW

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only